The correct answer is 5:
Levels of BCR::ABL1 mRNA in peripheral blood from patients on treatment serve as a surrogate for disease burden, and strongly correlate with outcome. Monitoring of response should be done by quantitative polymerase chain reaction at least every 3 months, until an MMR is achieved and confirmed.
Reference:
Apperley JF, Milojkovic D, Cross NCP, et al. 2025 European LeukemiaNet recommendations for the management of chronic myeloid leukemia. Leukemia. 2025;39:1797–1813. doi:10.1038/s41375-025-02664-w.
Interested in receiving LearningMonday questions to your inbox? Subscribe here: https://eha.fyi/subscribe
Would you like to contribute and submit a clinical case for #LearningMondays, please visit the submission and information page here on the EHA website. https://ehaweb.org/education-training/test-and-tools/eha-learning-mondays
No comments:
Post a Comment